RAD-x continues Buy & Build with acquisition of Swiss Medical Imaging Centers - Gilde Healthcare

RAD-x continues Buy & Build with acquisition of Swiss Medical Imaging Centers

13. Februar 2018

Utrecht, The Netherlands – RAD-x, a France-based operator in diagnostic imaging and a portfolio company of Gilde Healthcare, announced that it has acquired Swiss Medical Imaging Investment SA (SMII), which operates the imaging centres Centre d’Imagerie Médicale de la Chaux-de-Fonds, Centre d’Imagerie Médicale du Chablais and Centre d’Imagerie Médicale du Chablais Valaisan.

SMII is a leading diagnostic imaging provider in the Swiss cantons of Neuchâtel, Vaud and Valais and was founded and developed by the radiology entrepreneur Dr. Pierre Chevalley, who as part of this transaction becomes a shareholder in RAD-x.

With the acquisition of SMII, RAD-x expands its national reach and capabilities and strengthens its position as the partner of choice for diagnostic imaging centres and radiologists by combining medical excellence with state of the art management capabilities. With this transaction RAD-x is now able to offer the full range of imaging services from general to very specialized imaging as well as interventional radiology. Next to its expansion in Switzerland, RAD-x is progressing on its development in Germany and France.

 

About Gilde Healthcare
Gilde Healthcare is a specialized European healthcare investor managing two business lines: a venture & growth capital fund and a lower mid-market buy-out fund. Gilde Healthcare’s venture & growth capital fund invests in medtech, diagnostics, digital health and therapeutics. The portfolio companies are based in Europe and North America. Gilde Healthcare’s lower mid-market buy-out fund invests in profitable European healthcare services companies with a focus on the Benelux and Dach-region. The portfolio consists of healthcare providers, suppliers of medical products and other service providers in the healthcare market. Since 2001 Gilde Healthcare has raised €800 million ($1 billion) for its specialized funds. For more information, visit the company’s website at www.gildehealthcare.com

Gilde Healthcare company ProVerum Announces Completion of Enrollment for the ProVIDE Clinical Study for BPH and First-use of its New Flexible, Steerable Delivery System

ProVerum Limited, an Irish medical device company developing a minimally invasive solution to treat benign prostatic hyperplasia (BPH) in the doctor's office, today announced completion of enrollment of the ProVIDE pivotal clinical trial to evaluate...
21. März 2024

Gilde Healthcare veräussert RAD-x an ein konsortium aus Swiss Life Asset Managers und Vesper Infrastructure Fund I

Gilde Healthcare´s Private Equity Fund (“Gilde Healthcare”), ein auf das Gesundheitswesen spezialisierter Investor, hat eine bindende Vereinbarung über den Verkauf seiner Mehrheitsbeteiligung an RAD-x an ein Konsortium aus Swiss Life Asset Managers und Vesper Next...
18. März 2024

Gilde Healthcare company NIZO acquires lactic acid facility and strengthens partnership with DSM-firmenich

NIZO food research B.V. (“NIZO”) is proud to announce the signature of a long-term contract manufacturing partnership with dsm-firmenich. This strategic alliance encompasses the acquisition of the neighboring lactic acid facility from Vika Nutrition B.V.,...
29. Februar 2024